ArticleAntibiotics (Basel, Switzerland)2020
Characterization and Therapeutic Potential of Bacteriophage-Encoded Polysaccharide Depolymerases with β Galactosidase Activity against
Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Characterization and therapeutic potential of DepZ57, a stable depolymerase targeting hypervirulent K57Applied and environmental microbiology · 2026Article
- Phage-Encoded Depolymerase DepKP144 with Therapeutic Potential Against Both K1- and K2-TypeInternational journal of molecular sciences · 2026Article
- DposFinder: an interpretable transformer model for predicting phage-derived polysaccharide depolymerases and their host capsular serotypes.Genome medicine · 2026Article
- Evaluating Proteus mirabilis phage vB_PmiA_PM1 efficacy against catheter-associated urinary tract infections in artificial urine and laboratory media.BMC microbiology · 2026Article
- Characterization and genomic insights into bacteriophages Kpph1 and Kpph9 against hypervirulent carbapenem-resistantVirulence · 2025Article
- Phages adapt to recognize an O-antigen polysaccharide site by mutating the "backup" tail protein ORF59, enabling reinfection of phage-resistantEmerging microbes & infections · 2025Article
- Characterization and Therapeutic Potential of Three Depolymerases Against K54 Capsular-TypeMicroorganisms · 2025Article
- Evolution of enteric viruses in the progression of colorectal cancer via the adenoma-carcinoma sequence pathway.Virus research · 2025Article
- Article
- Immunomodulatory Effect of Phage Depolymerase Dep_kpv74 with Therapeutic Potential Against K2-HypervirulentAntibiotics (Basel, Switzerland) · 2025Article
- Capsular Polysaccharide as a Potential Target in Hypervirulent and Drug-ResistantInfection and drug resistance · 2025Review
- Phage-antibiotic combinations againstFrontiers in microbiology · 2025Article
- Phage Therapy: A Promising Treatment Strategy against Infections Caused by Multidrug-resistantCurrent pharmaceutical design · 2025Review
- Specificity and diversity of Klebsiella pneumoniae phage-encoded capsule depolymerases.Essays in biochemistry · 2024Review
- Defense and anti-defense mechanisms of bacteria and bacteriophages.Journal of Zhejiang University. Science. B · 2024Article
- Review
- Characterization and genomic analysis of a novel bacteriophage BUCT_49532 lysing Klebsiella pneumoniae.Virus genes · 2023Article
- Autophagy, cell death, and cytokines inEmerging microbes & infections · 2023Review
- Exploring the enzymatic activity of depolymerase gp531 from Klebsiella pneumoniae jumbo phage RaK2.Virus research · 2023Article
- New Strategies to Kill Metabolically-Dormant Cells Directly Bypassing the Need for Active Cellular Processes.Antibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Bacteriophages and phage enzymes are considered as possible alternatives to antibiotics in the treatment of infections caused by antibiotic-resistant bacteria. Due to the ability to cleave the capsular polysaccharides (CPS), one of the main virulence factors of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.